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S228 Poster Session Iwho completed three psychometric instruments prior to priming for
stem cell collection and at approximately day 42 post ASCT. The
three instruments are the Functional Assessment of Cancer Therapy
– Bone Marrow Transplant (FACT-BMT), measuring quality of life;
Brief COPE, measuring coping with illness; and Profile of Mood
States (POMS) short form, measuring mood states.
In comparisons of patient and transplant characteristics including
(but not limited to) gender, race, diagnosis, length of stay, and read-
missions, the following significant differences were found between
patients 60+ and under 60 years of age: Patients 60+ had a slightly
longer length of stay (median 21 vs. 20 days, p5 0.013), were
more likely to have NHL (75% vs. 61%), and less likely to have
Hodgkins (2% vs.19%, p\0.001).
Many significant differences were found in quality of life scores
between patients 60+ and under 60. Patients 60+ reported better so-
cial, emotional, and functional well-being at both pre-transplant and
at day 42 post-transplant (p# 0.05). The 60+ group also reported
better physical well-being at pre-transplant compared to the under
60 group (p5 0.022). Regarding significant differences in coping,
the 60+ group used less coping techniques of self-distraction, behav-
ioral disengagement, venting, planning, humor, and self-blame, but
reported more acceptance in coping with illness (p# 0.05). There are
four significant differences between the two groups on mood states
but only at pre-transplant. The 60+ group reports less depression,
anger, tension, and confusion than the under 60 group (p# 0.05).
It is surprising patients over 60 report better quality of life, better
mood states, and less utilization of coping techniques. It seems
that older patients are more accepting of illness and impact on func-
tioning, perceive themselves as not needing as much support to cope,
and report less negative impact on mood states than their younger
counterparts.188
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Hematopoietic progenitor cell transplantation (HPCT) remains
a salvage therapy for both malignant and non-malignant disorders.
However, it may result in late sequelae which negatively influence
the quality of life. The aim of this study was to evaluate the long-
term impact of HPCT on the patients’ health status. Two hundred
thirty one patients, who survived over one year after allogeneic
HPCT were included into the study. The median age at HPCT
was 11.5 years (from 4 months to 18 years), the median follow-up pe-
riod was 3.5 years (from 13 months to 12 years). One hundred eighty
three subjects were transplanted due to malignant diseases (group I)
and forty eight due to non-malignant disorders (group II). The fre-
quency of late side effects, including chronic Graft-versus-Host Dis-
ease (GvHD), endocrinal dysfunctions and organs impairment, were
compared between two groups using chi2 test.
Only 65 (28.1%) patients in the study group did not suffer from
any health problems. During the follow-up 15 (8.2%) patients in
group I died due to late complications (6 cGvHD, 5 infections, 2 sec-
ond neoplasm, 1 pulmonary artery thrombosis, 1 haemorrhage). In
group II two (4.2%) patients died (1 cGvHD, 1 haemorrhage),
p5 0.34. The incidence of late sequelae in group I and II was docu-
mented respectively: cGvHD 86 (47%) vs 10 (20.8%), p5 0.001; oc-
ular complications 39 (21.3%) vs 4 (8.3%), p5 0.04; skin problems
69 (37.7%) vs 6 (12.5%), p5 0.0009; hormonal dysfunction 64
(35%) vs 19 (39.6%), p5 0.55; pulmonary complications 55 (30%)
vs 9 (18.7%), p5 0.12; bone and joint impairment 32 (17.5%) vs 4
(8.3%), p5 0.12; cardiological dysfunction 25 (13.7%) vs 5
(10.4%), p5 0.55; kidney problems 5 (2.7%) vs 3 (6.2%), p5 0.23;
neurological disorders 10 (5.5%) vs 1 (2.1%), p5 0.16; second neo-
plasm 3 (1.6%) vs 1 (2.1%), p5 0.83.
Conclusions: Majority of survivors after allogeneic HPCT de-
velop late sequelae. Patients transplanted with the diagnosis of ma-
lignant disease are at higher risk of cGvHD resulting in furthercomplications, mainly skin and ocular problems. Higher incidence
of cGvHD in this cohort of patients may be due to less intensive im-
munosupressive therapy in comparison to the subjects transplanted
due to non-malignant diseases. The impact of chemotherapy used
in the treatment of malignancies prior to HPCT should also be taken
into consideration. The multidisciplinary monitoring for a pro-
longed period of time after HPCT is strongly recommended.189
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Allogeneic stem cell transplantation (allo-SCT) can cause severe
adversed effects, which is associated with functional impairment
and muscle weakness. In this study, we analyzed factors affecting
muscle weakness after allo-SCT in 21 patients (13 male, 8 female)
who had allo-SCT at Ehime Prefectural Central Hospital from April
2007–March 2009, Patient ages ranged from 26–64 (median 46
years) at the time of allo-SCT. Sixteen patients received stem cells
from unrelated donors, and 5 received them from related donors.
A myeloablative conditioning regimen was chosen for 14 patients,
and 7 patients had a reduced intensity conditioning regimen. The pa-
tients received lower extremity muscle training while muscle
strength was measured at the same time by a therapeutic exercise sys-
tem (Strength Ergo 240, Mitsubishi Electric Corp., Tokyo, Japan).
Percent changes of lower extremity muscle strength before allo-
SCT and 100 days after allo-SCT for each patient was calculated,
and muscle strength was also compared using the Mann-Whitney
U test between groups divided by various factors. The average per-
cent change of lower extremity muscle strength was
-22.16 24.3%, and age group (26-46 vs. 47-64 years), sex, and con-
ditioning regimens (myeloablative or non-myeloablative) did not
significantly affect muscle strength. Patients who had higher does
of steroids showed a tendency towards greater decreases in muscle
strength (high dose, -31.06 21.0% vs. low dose, -12.36 24.8%,
P5 0.057). Source of stem cells (unrelated, -28.86 24.0% vs. re-
lated, -0.56 6.1%, P5 0.026), grades of acute GVHD (grades 0-2,
-15.46 19.1% vs. grades 3-4 -62.26 1.1%, P\0.01), and levels of
serum albumin ($3.4 g/dl, -12.56 16.5% vs. \3.4 g/dl,
-34.86 28.0%, P5 0.047) significantly affected the decrease of mus-
cle strength. Our study suggests that muscle strength may be affected
by the source of stem cells, nutritious status and complications after
allo-SCT, and, patients at risk should receive more intensive therapy
to prevent loss of muscle strength after transplantation.190
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There are limited data on the impact of intensity of conditioning
on QOL in patients undergoing alloHCT. We undertook a prospec-
tive study to evaluate the outcomes and QOL in patients with mye-
loid malignancies undergoing alloHCT using MY or RIC. 115
patients were enrolled from Jan 2005 to Sep 2008 and no significant
differences in the outcomes were observed in the two study cohorts at
1-year (abstract submitted separately).
Of 115 patients, 105 (91%) patients (MY, 44; RIC, 61) consented
to participate in QOL study with QOL assessments at baseline,
day30, day100, day180 and day365. QOL was assessed by the follow-
ing measures: European Organization for Research and Treatment
of Cancer core 30-item questionnaire (QLQ-C30), Functional As-
sessment of Cancer Therapy-bone marrow transplantation subscale
(FACT-BMT), FACT anaemia and fatigue subscale (FACT-An),
